Discover
VOR
Vor Biopharma Inc.
18.39
2 x 13.55
2 x 23.27
bid
ask
-
0.02
0.11%
2 @ 04:00 PM
18.91 +0.52 (2.83%)
| Ytd | 40.60% | |
| 1y | -35.70% |
17.98
day range
19.12
6.50
52 week range
65.80
| Open | 18.39 | Prev Close | 18.41 | Low | 17.98 | High | 19.12 | Mkt Cap | 996.48M |
| Vol | 1.37M | Avg Vol | 1.15M | EPS | -70.40 | P/E | N/A | Forward P/E | -4.97 |
| Beta | 1.73 | Short Ratio | 7.25 | Inst. Own | 69.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 14.93 | 200-d Avg | 17.05 | 1yr Est | 37.88 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-11-06 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-12 | 2025-06 | 0 | N/A | -1.61 | -282.46% |
| 2025-05-14 | 2025-03 | 0 | N/A | -0.01 | -4.00% |
| 2025-05-14 | 2025-03 | 0 | N/A | N/A | N/A |
| 2025-03-20 | 2024-12 | 0 | N/A | -0.19 | -76.00% |
| 2025-03-20 | 2024-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-14 | Wedbush | Upgrade | Neutral | Neutral |
| 2026-04-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-03-31 | Wedbush | Upgrade | Neutral | Neutral |
| 2026-03-30 | Jefferies | Upgrade | Buy | |
| 2026-03-19 | Wells Fargo | Upgrade | Overweight |
Profile
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-02-02 | ANG ROBERT M.D. | Chief Executive Officer | 921.74K | Stock Award(Grant) |
| 2025-02-12 | ATTAR EYAL C | Officer | 126.63K | Sale |
| 2025-02-02 | CHAKRABORTY TIRTHA | Officer | 221.27K | Stock Award(Grant) |
| 2025-02-02 | CHOI HAN WOOK | Chief Financial Officer | 52.50K | Stock Award(Grant) |
| 2025-07-08 | MAHATME SANDESH | Chief Financial Officer | 13.88M | Stock Award(Grant) |
| 2025-10-16 | RA CAPITAL HEALTHCARE FUND,L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | TCG Crossover Management, LLC | 5.67M | 105.52M | 10.47% |
| 2026-03-30 | RA Capital Management, L.P. | 5.40M | 100.53M | 9.97% |
| 2026-03-30 | FCPM III Services B.V. | 4.12M | 76.58M | 7.60% |
| 2026-03-30 | Venrock Adviser, LLC | 3.04M | 56.58M | 5.61% |
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 2.54M | 47.32M | 4.69% |
| 2026-03-30 | Caligan Partners, LP | 1.93M | 35.81M | 3.55% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-04-29 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.19M | 22.05M | 2.19% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.07M | 19.81M | 1.97% |
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.04M | 19.32M | 1.92% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 333.54K | 6.20M | 0.62% |
| 2026-04-29 | Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 156.22K | 2.91M | 0.29% |
| 2026-02-27 | BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 115.08K | 2.14M | 0.21% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2025-09-19 |